Molina Healthcare, Inc. reaffirmed earnings guidance for the full year 2024 . For the year, Premium revenue is expected to be approximately $38 billion, an increase of approximately 17% from the full year 2023. While the Company is experiencing underlying strength in its core business, its full year guidance is unchanged to account for any potential earnings headwind in the second half of the year from potential contract losses in Virginia and Florida.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
309.6 USD | -1.23% | -1.60% | -14.32% |
May. 30 | JPMorgan Adjusts Price Target on Molina Healthcare to $420 From $435 | MT |
May. 30 | Baird Initiates Molina Healthcare With Outperform Rating, $405 Price Target | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.32% | 18.14B | |
+14.29% | 125B | |
+12.91% | 96.05B | |
-23.16% | 42.39B | |
-5.93% | 37.25B | |
-25.77% | 2.63B | |
-3.14% | 1.59B | |
+15.53% | 546M |
- Stock Market
- Equities
- MOH Stock
- News Molina Healthcare, Inc.
- Molina Healthcare, Inc. Re-Affirms Earnings Guidance for the Full Year 2024